References
- Davies MJ, Thomas AC. Plaque fissuring: the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. Br Heart J 1985: 53(4): 363–73
- Cairns JA, Collins R, Foster V, et al. Coronary thrombolysis. Chest 1989: 95(2 Suppl): 73-87S
- Braun wald E. Thrombolytic reperfusion of acute myocardial infarction: resolved and unresolved issues. J Am Coll Cardiol 1988: 12(6 Suppl A): 85-92A
- Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis in myocardial infarction [TlMI] trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation 1987: 76(1): 142–54
- ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988: 2(8607): 349–60
- Yusuf S. Interventions that potentially limit myocardial infarct size: overview of clinical trials. Am J Cardiol 1987: 60(2): 11–7A
- Yusuf S, Peto R, Lewis J, et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985: 27(5): 335–71
- ISIS-1 (First International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. Lancet 1986: 2(8498): 57–66
- Yusuf S, Collins R, MacMahon S, et al. Effect of intravenous nitrates on mortality in acute myocardial infarction: an overview of the randomised trials. Lancet 1988: 1(8594): 1088–92
- The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988: 319(7): 385–92
- Selected readings
- Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986: 1(8478): 397–402
- Jugdutt BI, Warnica JW. Intravenous nitroglycerin therapy to limit myocardial infarct size, expansion, and complications: effect of timing, dosage, and infarct location. Circulation 1988: 78(4): 906–19
- O'Neill WW, Topol EJ, Pitt B. Reperfusion therapy of acute myocardial infarction. Prog Cardiovasc Dis 1988: 30(4): 235–66
- Passamani E, Hodges M, Herman M, et al. The Thrombolysis in Myocardial Infarction (TIMI) phase II pilot study: tissue plasminogen activator followed by percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1987: 10(5 Suppl B): 51–64B
- Sheehan FH, Braunwald E, Canner P, et al. The effect of intravenous thrombolytic therapy on left ventricular function: a report on tissue-type plasminogen activator and streptokinase from the Thrombolysis in Myocardial Infarction (TIMI Phase I) trial. Circulation 1987: 75(4): 817–29
- Simoons ML, Arnold AE, Betriu A, et al. Thrombolysis with tissue plasminogen activator in acute myocardial infarction: no additional benefit from immediate percutaneous coronary angioplasty. Lancet 1988: 1(8579): 197–203
- Topol EJ, Califf RM, Kereiakes DJ, et al. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) trial. J Am Coll Cardiol 1987: 10(5 Suppl B): 65–74B